Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UL46
UPID:
PSME2_HUMAN
Alternative names:
11S regulator complex subunit beta; Activator of multicatalytic protease subunit 2; Proteasome activator 28 subunit beta
Alternative UPACC:
Q9UL46; Q15129
Background:
Proteasome activator complex subunit 2, also known as 11S regulator complex subunit beta, plays a crucial role in immunoproteasome assembly, vital for efficient antigen processing. This protein, identified by the accession number Q9UL46, is a part of the PA28 activator complex, significantly enhancing the generation of class I binding peptides by modifying the proteasome's cleavage pattern.
Therapeutic significance:
Understanding the role of Proteasome activator complex subunit 2 could open doors to potential therapeutic strategies.